CELH
Celsius Holdings, Inc.
CELH's fundamentals are strong and it looks cheap: trading at 35x earnings, less than half its usual 142x. Analysts expect strong earnings growth, though they disagree widely on how much.
SGRX
Sangrix Inc.
There isn't enough reported data to score SGRX yet.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SGRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Strong |
SGRX's balance sheet is currently strong, but its profitability is weak. There isn't enough data to rate its revenue and cash flow.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
SGRX PE Valuation
SGRX has no meaningful PE right now: it lost money over the past year.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
SGRX Forward outlook
There aren't enough analyst estimates for SGRX to show an outlook.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH has the edge over SGRX in the latest year-over-year earnings comparison.
SGRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2023 | -$2,553.56 | -630% |
| Q2 2022 | $481.94 | +$12,848.06 |
| Q2 2021 | -$12,366.12 | -$10,408.17 |
| Q2 2020 | -$1,957.95 | -204% |
SGRX lost $84.00 per share over the past year, a smaller loss than the year before.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over SGRX in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH's operating margin was 20% last quarter, up 31 points from the same quarter a year ago.
SGRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $6.3M | +3155% |
| Q2 2022 | $192.4K | -100% |
| Q2 2021 | $80.5M | -27% |
| Q2 2020 | $110.6M | +7.8% |
SGRX's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -234% | -234 points |
| Q2 2023 | -452% | -458 points |
| Q2 2022 | -3176% | N/A |
| Q2 2021 | -16% | N/A |
| Q2 2020 | 0.5% | N/A |
| Q2 2019 | 5.4% | N/A |
SGRX's operating margin was −234% last quarter, down 234 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
SGRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2023 | -$6.9M | +$15.7M |
| Q2 2020 | -$6.6M | -$1.3M |
SGRX and CELH do not have enough comparable growth data to identify a winner.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over SGRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
SGRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +131% | +15.5K shares |
| 1 year | +640% | +23.6K shares |
SGRX has 27,304 diluted shares, up 640% from a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has more cash than debt.
SGRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | 0.5x | Very low |
SGRX's net debt is less than a year of its operating earnings (EBITDA).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
SGRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.8 | Oversold |
| Stochastic | 4.0 | Oversold |
SGRX's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
SGRX PE vs Consumer Defensive Sector
| Metric | SGRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
SGRX has no meaningful PE right now: it lost money over the past year.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has the edge over SGRX on trend strength, trading above more of its moving averages.
SGRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.78 | 49% below |
| 20 week MA | $2.55 | 84% below |
| 50 week MA | $14.7 | 97% below |
| 100 week MA | $65.4 | 99% below |
| 200 week MA | $572.8 | 100% below |
SGRX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH has the edge over SGRX on returns for 2026, with the stronger performance.
SGRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36,540.0 | $8,100.0 | -78% |
| 2021 | $8,100.0 | $12,600.0 | +56% |
| 2022 | $12,600.0 | $1,468.8 | -88% |
| 2023 | $1,468.8 | $1,245.0 | -15% |
| 2024 | $1,245.0 | $273.0 | -78% |
| 2025 | $273.0 | $53.5 | -80% |
| 2026 YTD | $53.5 | $0.40 | -99% |
SGRX has finished four years in a row lower, and it's down 99% so far in 2026.